Please assess the completion status of the following clinical trial:

Trial Title: Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV positive~2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)~Exclusion Criteria:~1. Not on cART and a CD4 \<500 at the time of screening~2. Patients on cART for \>6 months with a HIV viral load \>400 copies~3. Disallowed co-medication that cannot be stopped or replaced~4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic well-controlled HBV (HBV-DNA \<below the limit of detection) is allowed if fibroscan excludes \>F1 fibrosis~5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse transcriptase inhibitors and an allowed third agent which can be raltegravir (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Grazoprevir/elbasvir single tablet regimen (100/50mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).